Katherine Kalin Biography and Net Worth



Ms. Kalin has been a director of the Company since August 2022. Ms. Kalin currently serves as a non-executive director on the boards of Genfit S.A. (NASDAQ: GNFT), a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm (Audit & Finance Committees), and FemHealth Ventures, a venture capital firm that seeks to invest in women’s health. She was a member of the board of directors of Athersys (NASDAQ: ATHX), a biotech focused on regenerative medicine from 2020 to 2022 (Audit and Compensation Committees) and Clinical Genomics, a private, biotech company dedicated to improving patient outcomes through early detection of colorectal cancer (Audit and Financial Risk Committee) from 2018 to 2021. She currently serves as a trustee for a not-for-profit organization, the Summit Foundation, a 501(c)(3) community foundation that fosters local philanthropy. Ms. Kalin has more than 25 years of experience in healthcare and professional services, most recently at Celgene, where she led Corporate Strategy from 2012 to 2017, and at Johnson & Johnson, where she held executive leadership roles in marketing, sales and new business development from 2002 to 2011. Prior to that, Ms. Kalin was a partner in the global healthcare practice at McKinsey & Co., from 1990 to 2002. Her healthcare industry experience spans pharmaceuticals, diagnostics, medical devices, and digital health. Earlier in her career, she served as a Manager in Corporate Finance at Nomura International in the U.K. and Japan from 1984 to 1988. She has a B.A. from Durham University, U.K. and an M.B.A. from Harvard Business School.

What is Katherine Bach Kalin's net worth?

The estimated net worth of Katherine Bach Kalin is at least $607.61 thousand as of November 19th, 2025. Kalin owns 104,400 shares of SELLAS Life Sciences Group stock worth more than $607,608 as of March 11th. This net worth approximation does not reflect any other investments that Kalin may own. Learn More about Katherine Bach Kalin's net worth.

How do I contact Katherine Bach Kalin?

The corporate mailing address for Kalin and other SELLAS Life Sciences Group executives is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. SELLAS Life Sciences Group can also be reached via phone at (646) 200-5278 and via email at [email protected]. Learn More on Katherine Bach Kalin's contact information.

Has Katherine Bach Kalin been buying or selling shares of SELLAS Life Sciences Group?

Katherine Bach Kalin has not been actively trading shares of SELLAS Life Sciences Group during the last ninety days. Most recently, on Wednesday, November 19th, Katherine Bach Kalin bought 63,400 shares of SELLAS Life Sciences Group stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $100,806.00. Following the completion of the transaction, the director now directly owns 104,400 shares of the company's stock, valued at $165,996. Learn More on Katherine Bach Kalin's trading history.

Who are SELLAS Life Sciences Group's active insiders?

SELLAS Life Sciences Group's insider roster includes Katherine Kalin (Director), and Jane Wasman (Director). Learn More on SELLAS Life Sciences Group's active insiders.

Are insiders buying or selling shares of SELLAS Life Sciences Group?

During the last twelve months, SELLAS Life Sciences Group insiders bought shares 3 times. They purchased a total of 93,400 shares worth more than $149,406.00. The most recent insider tranaction occured on November, 19th when Director Katherine Bach Kalin bought 63,400 shares worth more than $100,806.00. Insiders at SELLAS Life Sciences Group own 1.2% of the company. Learn More about insider trades at SELLAS Life Sciences Group.

Information on this page was last updated on 11/19/2025.

Katherine Bach Kalin Insider Trading History at SELLAS Life Sciences Group

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2025Buy63,400$1.59$100,806.00104,400View SEC Filing Icon  
See Full Table

Katherine Bach Kalin Buying and Selling Activity at SELLAS Life Sciences Group

This chart shows Katherine Bach Kalin's buying and selling at SELLAS Life Sciences Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SELLAS Life Sciences Group Company Overview

SELLAS Life Sciences Group logo
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $5.82
Low: $5.67
High: $6.00

50 Day Range

MA: $4.27
Low: $3.46
High: $5.96

2 Week Range

Now: $5.82
Low: $0.95
High: $6.14

Volume

6,608,527 shs

Average Volume

6,238,836 shs

Market Capitalization

$829.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18